We reported previously that the forced expression of the chemokine BRAK/CXCL14 in head and neck squamous cell carcinoma cells decreased the rate of tumor formation and size of tumor xenografts in athymic nude mice and SCID mice. In order to clarify the expression of BRAK/ CXCL14 affected either the settlement of carcinoma cells in host tissues in vivo or proliferation of the colonized carcinoma cells or both, we prepared oral floor carcinoma-derived HSC-2 cells in which BRAK/CXCL14 expression was induced upon doxycycline treatment. Then 30 nude mice were separated into 3 groups composed of 10 mice per group: Group I, the control, in which the engineered cells were directly xenografted onto the back of the mice; Group II, the cells were xenografted and then the mice were treated with doxycycline; and Group III, the cells were pretreated with doxycycline during culture, and the host mice were also treated with the drug before and after xenografting. The effects of BRAK/CXCL14 expression were examined by measuring the tumor size. The order of the size of tumor xenografts was Group I > II > III, even though the growth rate of the engineered cells was the same whether or not the cells were cultured in the presence of the drug. In addition, the size of tumors was significantly down-regulated after xenografting the doxycycline-pretreated cells in Group III. These data indicate that BRAK/CXCL14 expression in oral floor carcinoma cells reduced both the rate of settlement and the proliferation of the cells in vivo after settlement of the cells.
Chemokines are a family of small (8-14 kDa) mostly basic, structurally related chemotactic cytokines, and they function as leukocyte subtype-selective chemo-attractants (29, 30) . A complex network of chemokines and their receptors influences the development of primary tumors and metastasis (2, 19, 29) . First detected in breast and kidney, BRAK is also called CXC chemokine ligand 14 (CXCL14), and was reported to induce B cell, monocyte (26) , and dendritic cell infiltration into normal and tumour tissues (25) and to inhibit angiogenesis (23) . Generally, BRAK/CXCL14 is expressed universally and abundantly in normal tissues but is absent from or expressed only in a very small amount in cancerous tissues in vivo and in carcinoma cells in culture, including head and neck squamous cell carcinoma (HNSCC) cells (7, 9, 11, 16, 23) . On the other hand, heightened BRAK/CXCL14 expression has been reported to occur in adenocarcinomas such as prostate (22) , breast cancer (1) and pancreatic cancer cells (28) . These data suggest that the effects of BRAK/CXCL14 on the development and progression of cancer might be quite different between HN-
Construction of Tet-on BRAK vector and preparation of Tet-on BRAK HSC-2 cells. CSII-TRE-Tight-
RfA was generated by replacing the EF1a promoter in CSII-EF-RfA (a gift from Dr. H. Miyoshi, RIK-EN) with a tetracycline-inducible promoter, TRETight, from pTRE-Tight (Clontech). Lentiviral vector plasmid, CSII-TRE-Tight-EGFP was constructed by recombination using the Gateway system (Invitrogen) as described previously (18) . The HS4 chromatin insulator from the chicken β-globin locus control region (4) was inserted into the BspE1 site in the 3'-LTR of CSII-TRE-Tight-EGFP to generate CSII(ins)-TRE-Tight-EGFP. CSII(ins)-TRE-Tight-DEST was constructed by recombination between CSII(ins)-TRE-Tight-EGFP and pDONR221. BRAK cDNA was amplified by PCR and first recombined into pDONR221 and then recombined into CSII(ins)-TRE-Tight-DEST to generate CSII(ins)-TRE-Tight-BRAK. The recombinant lentiviruses with the vesicular stomatitis virus G glycoprotein were produced as described previously (12) . Production of recombinant retroviruses was described elsewhere (13) . HSC-2 cells were infected with PQCXIN-TetON retroviruses and selected in the presence of G418 (800 μg/mL). The Tet-on HSC-2 cells were then infected with CSII(ins)-TRE-Tight-BRAK or enhanced green fluorescent protein (EGFP) expressing lentiviruses at the multiplicity of infection of more than 5 so as to generate Tet-on BRAK-and Tet-on EGFP-HSC-2 cells, respectively.
Cells and cell culture. HSC-2 cells derived from an oral floor carcinoma were obtained from the Japanese Collection of Research Bioresources (JCRB). The cells were cultured in Dulbecco's modified Eagle's medium containing gentamicin sulfate (50 mg/L), Fungizone (250 mg/L) and 10% FBS in the absence or the presence of various concentrations of doxycycline. The cells were cultured at 37°C under 95% air and 5% CO 2 and routinely passaged by treatment with 0.25% trypsin/1 mM ethylenediaminetetraacetic acid in PBS (−). The growth rate of the cells was determined by TetraColor ONE assay or by measuring the number of cells with a Coulter ZI Counter (Coulter Electronics Ltd., England).
Western blot analysis. We determined BRAK/ CXCL14 and β-actin protein levels by using Western blotting as previously reported (16) . Cells were lysed with Laemmli buffer consisting of 62.5 mM Tris-HCl (pH 6.8) containing 2% SDS, 8% glycerol, SCC and adenocarcinoma. We reported previously that the forced expression of BRAK/CXCL14 in tongue carcinoma cells decreased the rate of tumor formation and size of tumor xenografts in athymic nude mice (16) and SCID mice (17) . In these experiments on cloned cells with an upregulated BRAK/CXCL14 protein expression, the growth of these cells under culture conditions was the same as that of control mock vector-transfected cells. However, the migration rate of the BRAK/CXCL14-expressing cells in vitro was significantly slower than that of the mock-vector transfected cells and attachment of the cells to collagen was much faster than the control cells (21) . Recent progress in cancer research has shown that cancerous tissues in vivo are derived from colonies of cancer stem cells (3, 10, 14, 18) . These data raised 3 possibilities regarding the apparent slower growth rate of xenografted BRAK/CXCL14-expressing tumor cells. The first is that the ratio of stem cell-like cells among the BRAK/CXCL14-expressing cells was smaller, and thus a smaller number of carcinoma cells settled in the tissues of the host mice. The second possibility is that the growth rate of BRAK/CXCL14-expressing cells in vivo was slower than that of mock-vector transfected cells. The third one is that both the rate of settlement and proliferation of the cells in vivo after settlement of the cells was reduced. In order to assess either BRAK/CXCL14 expression in tumor cells regulates settlement of tumor cells in the tissue or proliferation of the colonized tumour cells or both, we employed doxycycline-inducible HSC-2 cells, which express a high amount of BRAK/CXCL14 proteins only in the presence of doxycycline (8) , a derivative of tetracycline (24), referred to Tet-on BRAK HSC-2 cells.
MATERIALS AND METHODS
Materials. Dulbecco's modified Eagle's medium was obtained from Sigma (Tokyo, Japan), and gentamicin sulfate, Trypsin 250 and sucrose were from Wako Pure Chemical Industries (Osaka, Japan). Mg 2+ -Ca 2+ -free phosphate-buffered saline tablets PBS (−) and doxycycline were purchased from TA-KARA BIO (Shiga, Japan). Fungizone came from Invitrogen (Carlsbad, CA, USA); and fetal bovine serum (FBS) from Thermo Electron (Melbourne, Australia). TetraColor ONE reagent for determination of cell proliferation was from Seikagaku Corporation (Tokyo, Japan). kit (Vector Laboratories, Inc. Burlingame, CA) according to the manufacturer's instructions, as described previously (27) . Areas positively stained with anti-CD31 or anti-α smooth muscle actin antibodies were measured in 5 randomly chosen visual fields at ×200 magnification by use of a Biozero microscope (KEYENCE, Tokyo, Japan) and VH analyzer software (KEYENCE).
Statistical analysis. Student's t-test was used to assess statistically significant differences between 2 groups in vitro cell growth and in vivo tumor volumes with P < 0.05 being considered statistically significant. The Smirnov-Grubbs test was also used to determine statistically significant differences in the size of xenografted tumors.
RESULTS

Production and characterization of Tet-on BRAK HSC-2 cells
We first tried to produce doxycycline-inducible BRAK-expressing cells by using a commercially available two-step system that employs transfection reagents; however, we could not obtain cells expressing BRAK/CXCL14 protein at a high enough level to be detected by Western blotting. Thus we prepared doxycycline-inducible BRAK-expressing cells using retrovirus-and lentivirus-mediated gene transfer. Tet-on BRAK HSC-2 cells obtained here expressed BRAK/CXCL14 in both time-and doxycycline dose-dependent manners; and over a 10 times higher level of BRAK protein was expressed after 24 h of treatment with 0.1 μg/mL of doxycycline than obtained without the drug (Fig. 1A and B) . In addition 100% of the cells expressed EGFP as observed under a fluorescence microscope when Teton EGFP HSC-2 cells were cultured in the presence of doxycycline (data not shown). The addition of various amounts of doxycycline to the culture medium of parental HSC-2 cells did not affect the growth rate of the cells (Fig. 2A) . Furthermore, the growth rate of Tet-on BRAK HSC-2 cells was not affected by the presence of 0.1 μg/mL doxycycline up-to 8 days (Doxy; Fig. 2B ), at which time the cells expressed 14 times more BRAK/CXCL14 than the control (see Fig. 1B ), indicating that the presence of exogenously added doxycycline or the expression of over a 10 times higher level of BRAK/CXCL14 proteins by the cells did not affect the growth of the tumor cells under the culture conditions used. 0.05% bromophenol blue and 5% 2-mercaptoethanol. The proteins were separated by electrophoresis in an SDS-15-20% polyacrylamide gel (SuperSep; Wako Pure Chemical Industries, Osaka, Japan) and transferred onto an Immobilon-P membrane at a constant voltage of 50 volts for 2 h. After blocked with Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE), the membrane was incubated for 1 h at room temperature with appropriate primary antibodies in TBS solution [20 mM Tris-HCl (pH 7.6) containing 137 mM NaCl and 0.05% Tween-20]. It was then incubated with horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG, as the secondary antibody, for 30 min at room temperature. Immunoreactive bands were visualized using LumiLight Western Blotting Substrate (Roche Diagnostics, Tokyo, Japan). Intensity of signals on the Western blot was calculated by Image Quant 5.1 (GE Healthcare, Tokyo, Japan).
Tumor growth in vivo. Cells (1 × 10 7 cells/site) were injected subcutaneously into female BALB/c nu/nu mice (specific pathogen-free; Clea Japan, Tokyo, Japan). The mice were kept under a 12-h light/ 12-h dark cycle and provided water containing 2-mg/mL doxycycline and 5% (w/v) sucrose or 5% sucrose solution only for control mice (24) . Tumor volume was calculated according to the following formula: (a × b 2 )/2, where "a" is the longer and "b" is the shorter dimension (16) . All animal experiments in this study complied with the Guidelines of the Care and Use of Laboratory Animals of Kanagawa Dental College.
Immunohistochemical procedures. Tumor xenografts were removed from the mice and embedded in O.C.T compound (Tissue-Tek; Miles Inc., Elkhart, IN) and kept at −80°C. The frozen tissues were sectioned with a cryostat at 6 μm and the air-dried sections were incubated with rat anti-CD31antibody (ER-MP12; BMA Biomedicals, Switzerland, 1 : 800 dilution) as the 1st antibody and then with biotinylated rabbit anti-rat IgG (Vector Laboratories, Inc., Burlingame, CA; 1 : 250 dilution) as the 2nd antibody. Other sections were incubated with rabbit anti-α smooth muscle actin antibody (E184; Epitomics, Inc., Burlingame, CA; 1 : 100 dilution) as the 1st antibody followed by HRP-linked donkey antirabbit IgG (GE Healthcare, England; 1 : 50 dilution) as the 2nd antibody. For some sections the 1st antibody was omitted and used for a negative control. Histochemical color development was achieved by Vectastatin DAB (3,3'-diaminobenzidine) substrate
Effects of expression of BRAK protein by Tet-on BRAK HSC-2 cells in vivo
In order to examine the effect of BRAK expression on the growth of HSC-2 cells in vivo, we injected Tet-on BRAK HSC-2 cells subcutaneously into mice. After 13 days, when the average size of tumors had reached 200 mm 3 , we changed the drinking water from 5% sucrose solution [Group I: Doxy (−, −)] to 2 mg/mL doxycycline-containing 5% sucrose solution [Group II: Doxy (−, +)]. The growth of tumors was significantly slower in the doxycycline-treated mice than in the control animals (Fig.  3A) , and tumors obtained from the former expressed a significantly higher amount of BRAK protein, as observed by Western blotting (Fig. 3B) . When Teton BRAK HSC-2 cells were precultured for 7 days in the presence of 0.1 μg/mL of doxycycline before being injected into doxycycline-treated animals, the sizes of tumors at 6 days were significantly smaller than those at 3 days after the injection [Fig. 3A , Group III Doxy (+, +), see bracketed value], indicating that BRAK/CXCL14 expression affected the settlement of tumor cells. The sizes of tumors of Group III were always smaller than those of the tumors of doxycycline non-treated animals (Fig. 3A , Group I) and also those of animals treated with the drug after tumor cell injection (Fig. 3A, Group II) . Also, the expression level of BRAK/CXCL14 protein in the tumors from the doxycycline-treated animals was significantly higher than that of controls at 34 days after transplantation (Fig. 3B) . These finding thus indicate that BRAK/CXCL14 expression affected both the settlement of tumor cells and proliferation of the colonized cells. 7 Tet-on BRAK HSC-2 cells, and the animals were provided 5% sucrose-containing water (Group I). Other mice were given sucrose solution containing 2 mg/mL doxycycline starting at 13 days (black arrow) after implantation of the tumor cells (Group II). A third group of mice were implanted with Tet-on BRAK HSC-2 cells that had been precultured in the presence of 0.1 μg/mL of doxycycline for 7 days (Group III). These mice were provided doxycycline-supplemented water 7 days before (white arrow) implantation of the tumor cells. a, P < 0.05; b, P < 0.01; and c, P < 0.001 between group I and II or III. *, P < 0.05 between group II and III and **, P < 0.01 between day 3 and day 6 of group III. (B) Expression levels of BRAK/CXCL14 proteins in transplanted tumor cells in vivo 35 days after transplantation, as determined by Western blotting. ***, P < 0.001, as indicated by the bracket. sion of BRAK/CXCL14 is down-regulated. The expression is negatively regulated by the binding of epidermal growth factor (EGF) to its receptor (16); and when HNSCC cells are treated with gefitinib, an epidermal growth factor tyrosine kinase inhibitor, the expression of BRAK/CXCL14 protein increases under culture conditions (15) . Interestingly, the oral administration of gefitinib significantly (P < 0.001) reduces the growth of tumor xenografts of 3 HN-SCC cell lines (HSC-2, HSC-3 and HSC-4) in female athymic nude mice, which reduction is accompanied by an increase in BRAK expression specifically in the tumor tissue; this tumor-suppressing effect of the drug is not observed in the case of BRAK non-expressing cells (15) . Furthermore, the introduction of a vector expressing short hairpin RNA against BRAK reduces both the expression level of BRAK/CXCL14 in HSC-3 cells and the antitumor efficacy of gefitinib in vivo (15) . These data indicate an inverse relationship between BRAK expression levels in tumor cells and the tumor growth
Immunohistochemical studies
In order to clarify the reason for the suppression of the tumor growth in the BRA/CXCL14-expressing cells under the in vivo, but not under the in vitro situation, we examined the infiltration of blood vessels into the tumor tissue. When vascular endothelial cells in the tumor were immunohistochemically stained with anti-CD31 antibody, the number of CD31-positive endothelial cells at 1 day and 3 days after the xenografting was the same whether or not the tumor-bearing mice had been treated with doxycycline ( Fig. 4A and B) . However, when the sections were stained with anti-α smooth muscle actin antibody, a marker for smooth muscle cells, the area of positive staining surrounding the endothelial cells was significantly smaller in tumors 3 days after treatment with doxycycline ( Fig. 4A and B) .
DISCUSSION
In HNSCC cells, including HSC-2 cells, the expres- 
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Here we showed that the expression of BRAK/ CXCL14 protein induced in tumor cells by treatment with doxycycline in vivo resulted in significant reduction in the size of tumors compared with the size of the control mice (Fig. 3A and B) , even though expression of the protein under culture conditions did not affect the rate of growth of the cells ( Fig. 2A and B) . The results obtained here indicate that the expression of BRAK/CXCL14 itself without the co-presence of gefitinib is sufficient to reduce the growth rate of tumors in vivo. The present data showed significant down-regulation of the size of tumors shortly after tumor-cell xenografting when doxycycline-pretreated tumor cells were used and the host mice had been also pretreated with the drug before tumor cell xenografting. These results indicate that tumor cell settlement in the host tissues was also suppressed by the expression of BRAK/CXCL14 in the tumor cells. In order to investigate further the effect of BRAK/CXCL14 expression on tumor formation, we stained the tumor tissues in the xenografted mice with anti-CD31 antibody, a marker for vascular endothelial cells. We could not find any significant difference between doxycycline-treated and un-treated animals in terms of staining intensity ( Fig. 4A and  B) . However, a significant difference in the area positive for α smooth muscle actin was observed between tumors of doxycycline-treated and un-treated animals 3 days after injection of tumors ( Fig. 4A  and B) . It is reported that recombinant BRAK/ CXCL14 inhibits in vivo angiogenesis induced by IL-8 (CXCL8), basic FGF or VEGF and that binding of BRAK/CXCL14 to human umbilical vein endothelial cells and human dermal micro-vascular endothelial cells is not detectable (23) . Recently it was clarified that tumor blood vessels are atypical and immature, and they have poorly developed vessel walls that are invested inadequately with vascular smooth muscle cells (4, 10) . Our data coincide well with these reports and suggest the possibility that the target cell of BRAK/CXCL14 is the smooth muscle cell and not the vascular endothelial cell and that BRAK/CXCL14 inhibits the proliferation and/ or chemotaxis-directed movement of smooth muscle cells, which is essential for maturation of blood vessels. Thus, such inhibition would restrain the formation of functional vessels and consequently inhibit growth of tumors. In conclusion we showed, using Tet-on BRAK HSC-2 cells that expressed BRAK/CXCL14 protein
